Veregen is reported to be the first botanical drug approved for prescription use in the US and is patented through 2017, with additional applications pending which, if approved, would extend patents beyond 2020. Bradley licensed the product from MediGene and has exclusive marketing rights in the US.
In two Phase III randomized, double-blind, vehicle-controlled studies, Veregen proved effective in clearing both baseline and newly emerging external genital and perianal warts, with complete clearance in 53.6% of all patients studied who received Veregen as compared to 35.3% of those patients receiving vehicle.
Gerald Wachs, medical director of Bradley, said: “We believe that Veregen, an effective and safe alternative in the treatment of this condition, will enhance patient care.”